GlassScriptPhysician profile
Charles Cameron Evans
NPI 1619648961
$1,095.61
in general payments reported to CMS, 2019-2025
14 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.55 · 2022: $39.52 · 2023: $469 · 2024: $399 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,027.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $341.76 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $164.92 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $125.41 | 2023-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Glaxosmithkline, LLC. | $104.74 | 2023-2024 | Bexsero, Pediarix |
| Cranial Technologies, INC | $103.71 | 2022-2024 | Doc Band |
| Phadia US INC. | $64.19 | 2023-2025 | Immunocap |
| Alk-Abello, INC | $45.11 | 2024 | Grastek, Odactra, Ragwitek |
| Astrazeneca Pharmaceuticals LP | $32.92 | 2024 | Flumist Quadrivalent |
| Seqirus USA INC | $26.01 | 2025 | Flucelvax |
| Abbott Laboratories | $23.72 | 2023 | Id Now Instrument |
| Ultragenyx Pharmaceutical INC. | $18.31 | 2024 | Crysvita |
| Cipher Pharmaceuticals US LLC | $16.26 | 2025 | Natroba, Spinosad |
| Galderma Laboratories, L.P. | $14.72 | 2021 | |
| Ironshore Pharmaceuticals INC. | $13.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.